LT3528791T - Dispersinės kompozicijos - Google Patents
Dispersinės kompozicijosInfo
- Publication number
- LT3528791T LT3528791T LTEPPCT/EP2017/077030T LTEP2017077030T LT3528791T LT 3528791 T LT3528791 T LT 3528791T LT EP2017077030 T LTEP2017077030 T LT EP2017077030T LT 3528791 T LT3528791 T LT 3528791T
- Authority
- LT
- Lithuania
- Prior art keywords
- dispersive compositions
- dispersive
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621036404 | 2016-10-24 | ||
| PCT/EP2017/077030 WO2018077815A1 (en) | 2016-10-24 | 2017-10-23 | Dispersible compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3528791T true LT3528791T (lt) | 2024-05-27 |
Family
ID=60262899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2017/077030T LT3528791T (lt) | 2016-10-24 | 2017-10-23 | Dispersinės kompozicijos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11065198B2 (enExample) |
| EP (2) | EP3528791B1 (enExample) |
| JP (2) | JP7197474B2 (enExample) |
| KR (2) | KR102861006B1 (enExample) |
| CN (1) | CN110191704A (enExample) |
| CA (1) | CA3039562A1 (enExample) |
| DK (1) | DK3528791T3 (enExample) |
| ES (1) | ES2970870T3 (enExample) |
| FI (1) | FI3528791T3 (enExample) |
| HR (1) | HRP20240118T1 (enExample) |
| HU (1) | HUE064823T2 (enExample) |
| LT (1) | LT3528791T (enExample) |
| MA (1) | MA46563B1 (enExample) |
| MX (1) | MX2019004767A (enExample) |
| PL (1) | PL3528791T3 (enExample) |
| PT (1) | PT3528791T (enExample) |
| RS (1) | RS65159B1 (enExample) |
| SI (1) | SI3528791T1 (enExample) |
| SM (1) | SMT202400060T1 (enExample) |
| TW (1) | TWI821163B (enExample) |
| WO (1) | WO2018077815A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114126655A (zh) * | 2019-07-03 | 2022-03-01 | 爱尔兰詹森科学公司 | 用利匹韦林治疗儿科患者的hiv的方法 |
| JP2023503403A (ja) | 2019-11-29 | 2023-01-30 | シピオ ライフ サイエンシズ リミテッド | リルピビリンを含む組成物及び腫瘍又は癌を治療するためのその使用 |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| CN114392241B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种利匹韦林片及其制备方法 |
| GB202211231D0 (en) * | 2022-08-02 | 2022-09-14 | Glaxosmithkline Ip No 2 Ltd | Novel formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0181966A1 (en) * | 1984-11-13 | 1986-05-28 | Gist-Brocades N.V. | Compression-coated dispersible tablets |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AU2003266413B2 (en) | 2002-08-09 | 2009-04-02 | Janssen Pharmaceutica N.V. | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| CN101068597B (zh) * | 2004-09-02 | 2012-04-18 | 詹森药业有限公司 | 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐 |
| CN104586850A (zh) | 2004-09-02 | 2015-05-06 | 詹森药业有限公司 | 4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的盐酸盐 |
| PL1632232T6 (pl) * | 2004-09-02 | 2022-06-27 | Janssen Pharmaceutica Nv | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu |
| SI3366278T1 (sl) | 2006-06-23 | 2024-12-31 | Janssen Sciences Ireland Unlimited Company | Vodne suspenzije tmc278 |
| WO2015120014A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| WO2015136294A1 (en) | 2014-03-13 | 2015-09-17 | Cipla Limited | Pharmaceutical composittion comprising rilpivirine |
| WO2015176008A1 (en) | 2014-05-16 | 2015-11-19 | Vivus, Inc. | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use |
-
2017
- 2017-10-23 HR HRP20240118TT patent/HRP20240118T1/hr unknown
- 2017-10-23 PT PT177942752T patent/PT3528791T/pt unknown
- 2017-10-23 ES ES17794275T patent/ES2970870T3/es active Active
- 2017-10-23 FI FIEP17794275.2T patent/FI3528791T3/fi active
- 2017-10-23 WO PCT/EP2017/077030 patent/WO2018077815A1/en not_active Ceased
- 2017-10-23 RS RS20240158A patent/RS65159B1/sr unknown
- 2017-10-23 MX MX2019004767A patent/MX2019004767A/es unknown
- 2017-10-23 EP EP17794275.2A patent/EP3528791B1/en active Active
- 2017-10-23 KR KR1020247001197A patent/KR102861006B1/ko active Active
- 2017-10-23 LT LTEPPCT/EP2017/077030T patent/LT3528791T/lt unknown
- 2017-10-23 SM SM20240060T patent/SMT202400060T1/it unknown
- 2017-10-23 PL PL17794275.2T patent/PL3528791T3/pl unknown
- 2017-10-23 JP JP2019521720A patent/JP7197474B2/ja active Active
- 2017-10-23 SI SI201731486T patent/SI3528791T1/sl unknown
- 2017-10-23 EP EP23169649.3A patent/EP4248947A3/en active Pending
- 2017-10-23 CN CN201780065671.8A patent/CN110191704A/zh active Pending
- 2017-10-23 HU HUE17794275A patent/HUE064823T2/hu unknown
- 2017-10-23 MA MA46563A patent/MA46563B1/fr unknown
- 2017-10-23 DK DK17794275.2T patent/DK3528791T3/da active
- 2017-10-23 US US16/344,143 patent/US11065198B2/en active Active
- 2017-10-23 KR KR1020197014202A patent/KR20190073450A/ko not_active Ceased
- 2017-10-23 CA CA3039562A patent/CA3039562A1/en active Pending
- 2017-10-24 TW TW106136552A patent/TWI821163B/zh active
-
2021
- 2021-06-15 US US17/347,929 patent/US20220008333A1/en not_active Abandoned
-
2022
- 2022-10-14 JP JP2022165319A patent/JP2023011659A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3534968A4 (en) | ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS | |
| EP3722358A4 (en) | COMPOSITION | |
| DK3697376T3 (da) | Sammensætning | |
| DK3361870T3 (da) | Fungicidsammensætninger | |
| EP3334403A4 (en) | TOPICAL COMPOSITIONS | |
| EP3493800A4 (en) | CANNABIS | |
| LT3250182T (lt) | Dispersinės kompozicijos | |
| EP3339331A4 (en) | COMPOSITION | |
| EP3398996A4 (en) | COMPOSITION | |
| DK3334726T3 (da) | Plinabulinsammensætninger | |
| DK3528902T3 (da) | Ringegelsammensætning | |
| EP3397239A4 (en) | TOPICAL COMPOSITIONS | |
| EP3430073A4 (en) | COMPOSITION BASED ON A POLYARYLETHERKETONE COMPOSITION | |
| MA45090A (fr) | Compositions anticancéreuses | |
| EP3554470A4 (en) | COSMETIC COMPOSITIONS | |
| EP4234657C0 (en) | Compositions | |
| EP3395887C0 (en) | FLUOROR RUBBER COMPOSITION | |
| EP3480228A4 (en) | COMPOSITION | |
| EP3336527A4 (en) | X-ray fluorescence spectrometer | |
| DK3322295T3 (da) | Sammensætning | |
| DK3316857T3 (da) | Multifasiske sammensætninger | |
| LT3528791T (lt) | Dispersinės kompozicijos | |
| EP3556804A4 (en) | COMPOSITION | |
| DK3393254T3 (da) | Sammensætning | |
| LT3173071T (lt) | Maropitanto kompozicija |